INTRODUCTION AND OBJECTIVES: Patients at high risk of suffering cardiovascular events require medical treatment to optimize their lipid profile. The present analysis evaluates the lipid profiles among Spanish patients receiving statin therapy in the international DYSIS study. METHODS: DYSIS is a multinational cross-sectional study carried out in Canada and Europe (n=22,063). In Spain, 3710 patients treated with statin therapy for at least 3 months were included. We compared data relating to demographic parameters and cardiovascular risk profile. RESULTS: Complete lipid profiles of 3617 patients were recorded. Regarding the high cardiovascular risk patients with complete lipid profiles (n=2273), 78.9% had a disorder in at least one of the three main lipid parameters: low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and/or triglycerides. LDLc was not within target levels in 61.4% of these high risk patients; HDLc was abnormal in 25.3%, and triglycerides were elevated in 37.8%. Overall, LDLc was outside the target range in 63.1%, and 20.7% (n = 668) of those treated with statins were normal for all parameters. CONCLUSIONS: Most patients in this study who received statin therapy, particularly those at high cardiovascular risk, were not at the normal lipid parameter levels according to cardiovascular guidelines. Although it is necessary to wait for the final results of current studies on the use of combined lipid-modifying treatments, the management of lipid levels in Spain still has potential for improvement.
INTRODUCTION AND OBJECTIVES:Patients at high risk of suffering cardiovascular events require medical treatment to optimize their lipid profile. The present analysis evaluates the lipid profiles among Spanish patients receiving statin therapy in the international DYSIS study. METHODS: DYSIS is a multinational cross-sectional study carried out in Canada and Europe (n=22,063). In Spain, 3710 patients treated with statin therapy for at least 3 months were included. We compared data relating to demographic parameters and cardiovascular risk profile. RESULTS: Complete lipid profiles of 3617 patients were recorded. Regarding the high cardiovascular risk patients with complete lipid profiles (n=2273), 78.9% had a disorder in at least one of the three main lipid parameters: low-density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and/or triglycerides. LDLc was not within target levels in 61.4% of these high risk patients; HDLc was abnormal in 25.3%, and triglycerides were elevated in 37.8%. Overall, LDLc was outside the target range in 63.1%, and 20.7% (n = 668) of those treated with statins were normal for all parameters. CONCLUSIONS: Most patients in this study who received statin therapy, particularly those at high cardiovascular risk, were not at the normal lipid parameter levels according to cardiovascular guidelines. Although it is necessary to wait for the final results of current studies on the use of combined lipid-modifying treatments, the management of lipid levels in Spain still has potential for improvement.
Authors: Elisenda Climent; David Benaiges; Juan Pedro-Botet; Juana A Flores-Le Roux; Jose M Ramón; Montserrat Villatoro; Laia Fontané; Juan J Chillarón; Albert Goday Journal: Obes Surg Date: 2017-06 Impact factor: 4.129
Authors: Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla Journal: Biol Blood Marrow Transplant Date: 2016-08-30 Impact factor: 5.742
Authors: Z DeFilipp; R F Duarte; J A Snowden; N S Majhail; D M Greenfield; J L Miranda; M Arat; K S Baker; L J Burns; C N Duncan; M Gilleece; G A Hale; M Hamadani; B K Hamilton; W J Hogan; J W Hsu; Y Inamoto; R T Kamble; M T Lupo-Stanghellini; A K Malone; P McCarthy; M Mohty; M Norkin; P Paplham; M Ramanathan; J M Richart; N Salooja; H C Schouten; H Schoemans; A Seber; A Steinberg; B M Wirk; W A Wood; M Battiwalla; M E D Flowers; B N Savani; B E Shaw Journal: Bone Marrow Transplant Date: 2016-08-22 Impact factor: 5.483
Authors: Emma Forcadell Drago; Maria Rosa Dalmau Llorca; Carina Aguilar Martín; Ignacio Ferreira-González; Zojaina Hernández Rojas; Alessandra Queiroga Gonçalves; Carlos López-Pablo Journal: Int J Environ Res Public Health Date: 2020-11-19 Impact factor: 3.390
Authors: Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio Journal: Adv Ther Date: 2015-10-26 Impact factor: 3.845
Authors: Sami T Azar; Hadi Abu Hantash; Selim Jambart; Mohamed M El-Zaheri; Rachoin Rachoin; Amal Chalfoun; Layla Lahoud; Osama Okkeh; Peter Bramlage; Philippe Brudi; Baishali M Ambegaonkar Journal: Vasc Health Risk Manag Date: 2014-05-07
Authors: Zachariah DeFilipp; Rafael F Duarte; John A Snowden; Navneet S Majhail; Diana M Greenfield; José López Miranda; Mutlu Arat; K Scott Baker; Linda J Burns; Christine N Duncan; Maria Gilleece; Gregory A Hale; Mehdi Hamadani; Betty K Hamilton; William J Hogan; Jack W Hsu; Yoshihiro Inamoto; Rammurti T Kamble; Maria Teresa Lupo-Stanghellini; Adriana K Malone; Philip McCarthy; Mohamad Mohty; Maxim Norkin; Pamela Paplham; Muthalagu Ramanathan; John M Richart; Nina Salooja; Harry C Schouten; Helene Schoemans; Adriana Seber; Amir Steinberg; Baldeep M Wirk; William A Wood; Minoo Battiwalla; Mary E D Flowers; Bipin N Savani; Bronwen E Shaw Journal: Biol Blood Marrow Transplant Date: 2016-05-14 Impact factor: 5.742